problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl9305problendo-9305Research ArticleОбзорыReviewsКостно-суставные структурные нарушения при акромегалииBone and joint structural impairments in acromegalyhttps://orcid.org/0000-0001-9074-2291ЦориевТимур ТамерлановичTsorievTimur T.

Аспирант, Институт клинической эндокринологии, отделение нейроэндокринологии и остеопатий

MD, Postgraduate Student (PhD Student), Institute of Clinical Endocrinology, Department of Neuroendocrinology and Bone Diseases

timur.tsoriev@gmail.comhttps://orcid.org/0000-0002-6674-6441БелаяЖанна ЕвгеньевнаBelayaZhanna E.

Д.м.н., главный научный сотрудник, Институт клинической эндокринологии, заведующая отделением нейроэндокринологии и остеопатий

MD, PhD, Institute of Clinical Endocrinology, Head of Department of Neuroendocrinology and Bone Diseases

jannabelaya@gmail.com<p>ФГБУ &laquo;Национальный медицинский исследовательский центр эндокринологии&raquo; Минздрава России</p>Россия<p>Endocrinology Research Centre</p>Russian Federation201815052018642121129Copyright &#x00A9; Цориев Т.Т., Белая Ж.Е., 20182018Цориев Т.Т., Белая Ж.Е.Tsoriev T.T., Belaya Z.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/9305

Повышенные концентрации соматотропного гормона (СТГ) и инсулиноподобного фактора роста 1 (ИФР-1) в сыворотке крови у пациентов с акромегалией приводят к интенсификации костного обмена, о чем свидетельствуют увеличение уровня маркеров костного ремоделирования и возрастание риска низкотравматических переломов тел позвонков. Однако неоднократно отмечено, что минеральная плотность кости (МПК) при акромегалии (в том числе в активной стадии заболевания) остается нормальной или даже возрастает. Повышенная секреция СТГ/ИФР-1 вызывает структурные изменения позвонков и периферических суставов (образование остеофитов и гипертрофия суставного хряща), приводя к болевому синдрому и разнообразным деформациям суставного аппарата. Эти изменения объединяются под названием «акромегалическая артропатия». Она представляет собой достаточно специфическое осложнение заболевания. Скелетные осложнения акромегалии могут сохраняться и после радикального лечения, т.е. их течение и прогрессирование, по-видимому, не обязательно зависят от степени ремиссии основного заболевания. В данном обзоре суммированы современные представления о патофизиологии, клинике, диагностике и лечении костно-суставных осложнений акромегалии.

Elevated serum levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in patients with acromegaly result in intensified bone turnover, as evidenced by increased levels of bone remodeling markers and higher risk of low-traumatic vertebral fractures. However, it was repeatedly observed that bone mineral density (BMD) is normal or even increased in patients with acromegaly (including the active stage of the disease). Increased secretion of GH/IGF-1 causes structural changes in the vertebrae and peripheral joints (osteophyte formation and cartilage hypertrophy), resulting in pain and various deformities of the articular system. These changes are known under the common name «acromegalic arthropathy». It is quite specific complication of the disease. Skeletal complications of acromegaly can persist even after radical treatment, i.e., their course and progression, presumably, do not necessarily depend on the remission level of the underlying disease. This review summarizes the current understanding of the pathophysiology, clinical presentation, diagnosis, and treatment of osteo-articular complications of acromegaly.

акромегалияостеопорознизкотравматические переломытрабекулярная костная тканьакромегалическая артропатияacromegalyosteoporosislow-traumatic fracturestrabecular boneacromegalic arthropathyПоисково-аналитическая работа выполнена при поддержке гранта Президента Российской Федерации для молодых ученых (МД-3204.2017.7).ReferencesЭндокринология. Российские клинические рекомендации./ Под ред. Дедова И.И., Мельниченко Г.А. — М.: ГЭОТАР-Медиа; 2016. [Dedov II, Mel’nichenko GA, editors. Endocrinology. Russian clinical guidelines. Moscow: GEOTAR-Media; 2016. (In Russ.)].Эндокринология. Российские клинические рекомендации./ Под ред. Дедова И.И., Мельниченко Г.А. — М.: ГЭОТАР-Медиа; 2016. [Dedov II, Mel’nichenko GA, editors. Endocrinology. Russian clinical guidelines. Moscow: GEOTAR-Media; 2016. (In Russ.)].Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. doi: 10.1210/er.2002-0022Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. doi: 10.1210/er.2002-0022Mazziotti G, Bilezikian J, Canalis E, et al. New understanding and treatments for osteoporosis. Endocrine. 2012;41(1):58-69. doi: 10.1007/s12020-011-9570-2Mazziotti G, Bilezikian J, Canalis E, et al. New understanding and treatments for osteoporosis. Endocrine. 2012;41(1):58-69. doi: 10.1007/s12020-011-9570-2Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я., и др. Эпигенетические аспекты остеопороза. //Вестник Российской академии медицинских наук. — 2015. — Т. 70. — № 5. — C. 541-548. [Grebennikova TA, Belaya ZhE, Rozhinskaya LY, Mel’nichenko GA, Dedov II. Epigenetic aspects of osteoporosis. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2015;70(5):541-548. (In Russ.)]. doi: 10.15690/vramn.v70.i5.1440Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я., и др. Эпигенетические аспекты остеопороза. //Вестник Российской академии медицинских наук. — 2015. — Т. 70. — № 5. — C. 541-548. [Grebennikova TA, Belaya ZhE, Rozhinskaya LY, Mel’nichenko GA, Dedov II. Epigenetic aspects of osteoporosis. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2015;70(5):541-548. (In Russ.)]. doi: 10.15690/vramn.v70.i5.1440Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. Остеопороз — от редкого симптома эндокринных болезней до безмолвной эпидемии XX—XXI века. // Проблемы эндокринологии. — 2011. — Т. 57. — № 1. — С. 35-45. [Dedov II, Mel’nichenko GA, Belaya ZhE, Rozhinskaya LY. Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX—XXI centuries. Problemy Endokrinologii. 2011;57(1):35-45. (In Russ.)]. doi: 10.14341/probl201157135-45Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. Остеопороз — от редкого симптома эндокринных болезней до безмолвной эпидемии XX—XXI века. // Проблемы эндокринологии. — 2011. — Т. 57. — № 1. — С. 35-45. [Dedov II, Mel’nichenko GA, Belaya ZhE, Rozhinskaya LY. Osteoporosis: from a rare symptom of endocrine diseases to the tacit epidemic of XX—XXI centuries. Problemy Endokrinologii. 2011;57(1):35-45. (In Russ.)]. doi: 10.14341/probl201157135-45Wassenaar MJ, Biermasz NR, van Duinen N, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with longterm cure of acromegaly: a case-control study. Eur J Endocrinol. 2009;160(3):357-365. doi: 10.1530/EJE-08-0845Wassenaar MJ, Biermasz NR, van Duinen N, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with longterm cure of acromegaly: a case-control study. Eur J Endocrinol. 2009;160(3):357-365. doi: 10.1530/EJE-08-0845Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev.2008;29(5):535-559. doi: 10.1210/er.2007-0036Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev.2008;29(5):535-559. doi: 10.1210/er.2007-0036Lanyon L, Armstrong V, Ong D, Zaman G, Price J. Is estrogen receptor alpha key to controlling bones’ resistance to fracture? J Endocrinol. 2004;182(2):183-191. doi: 10.1677/joe.0.1820183Lanyon L, Armstrong V, Ong D, Zaman G, Price J. Is estrogen receptor alpha key to controlling bones’ resistance to fracture? J Endocrinol. 2004;182(2):183-191. doi: 10.1677/joe.0.1820183Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455-466. doi: 10.1016/j.jocd.2013.08.004Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455-466. doi: 10.1016/j.jocd.2013.08.004Цориев Т.Т., Белая Ж.Е., Мельниченко Г.А. Трабекулярный костный индекс – неинвазивный метод оценки качества костной ткани на основании рутинной двухэнергетической денситометрии. Перспективы использования в клинической практике. // Альманах клинической медицины. — 2016. — Т. 44. — № 4. — С. 462-476. [Tsoriev TT, Belaya ZhE, Mel’nichenko GA. Trabecular bone score — a non-invasive analytical method to evaluate bone quality based on routine dual-energy absorptiometry. Perspectives of its use in clinical practice. Almanaс of clinical medicine. 2016;44(4):462-476. (In Russ.)]. doi: 10.18786/2072-0505-2016-44-4-462-476Цориев Т.Т., Белая Ж.Е., Мельниченко Г.А. Трабекулярный костный индекс – неинвазивный метод оценки качества костной ткани на основании рутинной двухэнергетической денситометрии. Перспективы использования в клинической практике. // Альманах клинической медицины. — 2016. — Т. 44. — № 4. — С. 462-476. [Tsoriev TT, Belaya ZhE, Mel’nichenko GA. Trabecular bone score — a non-invasive analytical method to evaluate bone quality based on routine dual-energy absorptiometry. Perspectives of its use in clinical practice. Almanaс of clinical medicine. 2016;44(4):462-476. (In Russ.)]. doi: 10.18786/2072-0505-2016-44-4-462-476Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и др. Краткое изложение клинических рекомендаций по диагностике и лечению остеопороза Российской ассоциации эндокринологов. // Остеопороз и остеопатии. — 2016. — Т. 19. — № 3. — С. 28-36. [Melnichenko GA, Belaya ZhE, Rozhinskaya LY, et al. Summary of clinical guidelines for the diagnosis and treatment of osteoporosis of the Russian Association of Endocrinologists. Osteoporosis and osteopathy. 2016;19(3):28-36. (In Russ.)].Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и др. Краткое изложение клинических рекомендаций по диагностике и лечению остеопороза Российской ассоциации эндокринологов. // Остеопороз и остеопатии. — 2016. — Т. 19. — № 3. — С. 28-36. [Melnichenko GA, Belaya ZhE, Rozhinskaya LY, et al. Summary of clinical guidelines for the diagnosis and treatment of osteoporosis of the Russian Association of Endocrinologists. Osteoporosis and osteopathy. 2016;19(3):28-36. (In Russ.)].Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 1998;21(10):688-693. doi: 10.1007/bf03350799Longobardi S, Di Somma C, Di Rella F, et al. Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest. 1998;21(10):688-693. doi: 10.1007/bf03350799Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837-1844. doi: 10.1359/JBMR.050603Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837-1844. doi: 10.1359/JBMR.050603Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008;93(12):4649-4655. doi: 10.1210/jc.2008-0791Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008;93(12):4649-4655. doi: 10.1210/jc.2008-0791Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 1997;12(10):1729-1736. doi: 10.1359/jbmr.1997.12.10.1729Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res. 1997;12(10):1729-1736. doi: 10.1359/jbmr.1997.12.10.1729Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013;98(8):3402-3410. doi: 10.1210/jc.2013-1460Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013;98(8):3402-3410. doi: 10.1210/jc.2013-1460Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab. 2003;21(2):91-97. doi: 10.1007/s007740300015Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab. 2003;21(2):91-97. doi: 10.1007/s007740300015Bolanowski M, Daroszewski J, Medra M, et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2006;24(1):72-78. doi: 10.1007/s00774-005-0649-9Bolanowski M, Daroszewski J, Medra M, et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J Bone Miner Metab. 2006;24(1):72-78. doi: 10.1007/s00774-005-0649-9Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol. 2006;155(5):709-715. doi: 10.1530/eje.1.02285Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol. 2006;155(5):709-715. doi: 10.1530/eje.1.02285Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine. 2013;43(2):245-246. doi: 10.1007/s12020-012-9781-1Romijn JA. Acromegalic arthropathy: current perspectives. Endocrine. 2013;43(2):245-246. doi: 10.1007/s12020-012-9781-1Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013;98(4):1734-1741. doi: 10.1210/jc.2012-4073Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2013;98(4):1734-1741. doi: 10.1210/jc.2012-4073Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2015;100(2):384-394. doi: 10.1210/jc.2014-2937Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2015;100(2):384-394. doi: 10.1210/jc.2014-2937Потешкин Ю.Е., Пронин В.С., Мельниченко Г.А. и др. Влияние избытка гормона роста и ИФР-1 на костно-суставную систему при акромегалии. // Актуальная эндокринология. — 2015. — № 10. — С. 2. [Poteshkin YE, Pronin VS, Mel’nichenko GA, et al. Growth hormone and IGF-1 effects on articular and skeletal system in acromegaly. Relevant endocrinology. 2015;(10):2. (In Russ.)]. doi: 10.18508/endo3539Потешкин Ю.Е., Пронин В.С., Мельниченко Г.А. и др. Влияние избытка гормона роста и ИФР-1 на костно-суставную систему при акромегалии. // Актуальная эндокринология. — 2015. — № 10. — С. 2. [Poteshkin YE, Pronin VS, Mel’nichenko GA, et al. Growth hormone and IGF-1 effects on articular and skeletal system in acromegaly. Relevant endocrinology. 2015;(10):2. (In Russ.)]. doi: 10.18508/endo3539Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989;111(7):567-573. doi: 10.7326/0003-4819-111-7-567Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med. 1989;111(7):567-573. doi: 10.7326/0003-4819-111-7-567Lesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf). 1998;48(1):59-65. doi: 10.1046/j.1365-2265.1998.00349.xLesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf). 1998;48(1):59-65. doi: 10.1046/j.1365-2265.1998.00349.xPadova G, Borzi G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab. 2011;8(3):37-43.Padova G, Borzi G, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab. 2011;8(3):37-43.Griffith JF, Genant HK. New advances in imaging osteoporosis and its complications. Endocrine.2012;42(1):39-51. doi: 10.1007/s12020-012-9691-2Griffith JF, Genant HK. New advances in imaging osteoporosis and its complications. Endocrine.2012;42(1):39-51. doi: 10.1007/s12020-012-9691-2Ulivieri FM, Silva BC, Sardanelli F, et al. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014;47(2):435-448. doi: 10.1007/s12020-014-0280-4Ulivieri FM, Silva BC, Sardanelli F, et al. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014;47(2):435-448. doi: 10.1007/s12020-014-0280-4Marazuela M, Astigarraga B, Tabuenca MJ, et al. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993;52(6):419-421. doi: 10.1007/bf00571329Marazuela M, Astigarraga B, Tabuenca MJ, et al. Serum bone Gla protein as a marker of bone turnover in acromegaly. Calcif Tissue Int. 1993;52(6):419-421. doi: 10.1007/bf00571329Tsoriev TT, Grebennikova TA, Belaya ZE, et al. Bone turnover markers and serum sclerostin levels in patients with acromegaly. In: Kanis JA, Cosman F, editors. Osteoporos Int (Abstract Book). 27 Suppl 1. WCO-IOF-ESCEO 2016: Proceedings of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 2016 Apr 14-17; Malaga, Spain. Berlin: Springer; 2016;182-183.Tsoriev TT, Grebennikova TA, Belaya ZE, et al. Bone turnover markers and serum sclerostin levels in patients with acromegaly. In: Kanis JA, Cosman F, editors. Osteoporos Int (Abstract Book). 27 Suppl 1. WCO-IOF-ESCEO 2016: Proceedings of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 2016 Apr 14-17; Malaga, Spain. Berlin: Springer; 2016;182-183.Kamenicky P, Mazziotti G, Lombes M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35(2):234-281. doi: 10.1210/er.2013-1071Kamenicky P, Mazziotti G, Lombes M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35(2):234-281. doi: 10.1210/er.2013-1071Гребенникова Т.А., Белая Ж.Е., Цориев Т.Т. и др. Эндокринная функция костной ткани. //Остеопороз и остеопатии. — 2015. — Т. 18. — № 1. — С. 28-37. [Grebennikova TA, Belaya ZhE, Tsoriev TT, et al. The endocrine function of the bone tissue. Osteoporosis and osteopathy. 2015;18(1):28-37. (In Russ.)]. doi: 10.14341/osteo2015128-37Гребенникова Т.А., Белая Ж.Е., Цориев Т.Т. и др. Эндокринная функция костной ткани. //Остеопороз и остеопатии. — 2015. — Т. 18. — № 1. — С. 28-37. [Grebennikova TA, Belaya ZhE, Tsoriev TT, et al. The endocrine function of the bone tissue. Osteoporosis and osteopathy. 2015;18(1):28-37. (In Russ.)]. doi: 10.14341/osteo2015128-37Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997;7(3):226-230. doi: 10.1007/bf01622293Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int. 1997;7(3):226-230. doi: 10.1007/bf01622293Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly – a potential beneficial effect of growth hormone. Osteoporos Int. 2004;15(2):155-159. doi: 10.1007/s00198-003-1531-zVestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly – a potential beneficial effect of growth hormone. Osteoporos Int. 2004;15(2):155-159. doi: 10.1007/s00198-003-1531-zCooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985—1989. J Bone Miner Res. 1992;7(2):221-227. doi: 10.1002/jbmr.5650070214Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985—1989. J Bone Miner Res. 1992;7(2):221-227. doi: 10.1002/jbmr.5650070214Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164(4):475-483. doi: 10.1530/EJE-10-1005Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol. 2011;164(4):475-483. doi: 10.1530/EJE-10-1005Brzana J, Yedinak CG, Hameed N, et al. FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf). 2014;80(4):614-616. doi: 10.1111/cen.12262Brzana J, Yedinak CG, Hameed N, et al. FRAX score in acromegaly: does it tell the whole story? Clin Endocrinol (Oxf). 2014;80(4):614-616. doi: 10.1111/cen.12262Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite longterm biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013;98(12):4808-4815. doi: 10.1210/jc.2013-2695Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite longterm biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab. 2013;98(12):4808-4815. doi: 10.1210/jc.2013-2695Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003;26(12):1242-1247. doi: 10.1007/bf03349164Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003;26(12):1242-1247. doi: 10.1007/bf03349164Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294-302. doi: 10.1007/s11102-012-0420-xMelmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294-302. doi: 10.1007/s11102-012-0420-xLindsay R, Pack S, Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int. 2005;16(3):306-312. doi: 10.1007/s00198-004-1691-5Lindsay R, Pack S, Li Z. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int. 2005;16(3):306-312. doi: 10.1007/s00198-004-1691-5Jalava T, Sarna S, Pylkkänen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003;18(7):1254-1260. doi: 10.1359/jbmr.2003.18.7.1254Jalava T, Sarna S, Pylkkänen L, et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res. 2003;18(7):1254-1260. doi: 10.1359/jbmr.2003.18.7.1254Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA. 2007;298(23):2761-2767. doi: 10.1001/jama.298.23.2761Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA. 2007;298(23):2761-2767. doi: 10.1001/jama.298.23.2761Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15(7):1384-1392. doi: 10.1359/jbmr.2000.15.7.1384Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res. 2000;15(7):1384-1392. doi: 10.1359/jbmr.2000.15.7.1384Mazziotti G, Baracca M, Doga M, et al. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur J Endocrinol. 2012;167(6):865-872. doi: 10.1530/EJE-12-0566Mazziotti G, Baracca M, Doga M, et al. Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur J Endocrinol. 2012;167(6):865-872. doi: 10.1530/EJE-12-0566Diacinti D, Guglielmi G. Vertebral morphometry. Radiol Clin North Am. 2010;48(3):561-575. doi: 10.1016/j.rcl.2010.02.018Diacinti D, Guglielmi G. Vertebral morphometry. Radiol Clin North Am. 2010;48(3):561-575. doi: 10.1016/j.rcl.2010.02.018Vosse D, Heijckmann C, Landewé R, et al. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford). 2007;46(11):1667-1671. doi: 10.1093/rheumatology/kem135Vosse D, Heijckmann C, Landewé R, et al. Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford). 2007;46(11):1667-1671. doi: 10.1093/rheumatology/kem135Schousboe JT, Vokes T, Broy SB, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):92-108. doi: 10.1016/j.jocd.2007.12.008Schousboe JT, Vokes T, Broy SB, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11(1):92-108. doi: 10.1016/j.jocd.2007.12.008Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res. 2006;21(4):520-528. doi: 10.1359/jbmr.060112Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res. 2006;21(4):520-528. doi: 10.1359/jbmr.060112Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476-2482. doi: 10.1210/jcem.85.7.6699Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000;85(7):2476-2482. doi: 10.1210/jcem.85.7.6699Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol. 2010;163(1):15-20. doi: 10.1530/EJE-10-0125Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol. 2010;163(1):15-20. doi: 10.1530/EJE-10-0125Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170(6):893-899. doi: 10.1530/EJE-14-0097Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170(6):893-899. doi: 10.1530/EJE-14-0097Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51(5):611-618. doi: 10.1046/j.1365-2265.1999.00851.xColao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51(5):611-618. doi: 10.1046/j.1365-2265.1999.00851.xDieppe PA. Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Osteoarthritis Cartilage. 1995;3(2):73-77. doi: 10.1016/s1063-4584(05)80040-8Dieppe PA. Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Osteoarthritis Cartilage. 1995;3(2):73-77. doi: 10.1016/s1063-4584(05)80040-8Altman RD, Hochberg M, Murphy WAJr, et al. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995;3 Suppl A:3-70.Altman RD, Hochberg M, Murphy WAJr, et al. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995;3 Suppl A:3-70.Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. doi: 10.1136/ard.16.4.494Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. doi: 10.1136/ard.16.4.494Wassenaar MJ, Biermasz NR, Bijsterbosch J, et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis. 2011;70(2):320-325. doi: 10.1136/ard.2010.131698Wassenaar MJ, Biermasz NR, Bijsterbosch J, et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis. 2011;70(2):320-325. doi: 10.1136/ard.2010.131698Claessen KM, Kloppenburg M, Kroon HM, et al. Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res. 2013;23(5):159-164. doi: 10.1016/j.ghir.2013.05.003Claessen KM, Kloppenburg M, Kroon HM, et al. Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Horm IGF Res. 2013;23(5):159-164. doi: 10.1016/j.ghir.2013.05.003Biermasz NR, van’t Klooster KR, Wassenaar MJ, et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol. 2012;166(3):407-413. doi: 10.1530/EJE-11-0795Biermasz NR, van’t Klooster KR, Wassenaar MJ, et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. Eur J Endocrinol. 2012;166(3):407-413. doi: 10.1530/EJE-11-0795Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840. doi: 10.1186/1471-2474-13-168Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840. doi: 10.1186/1471-2474-13-168Bellamy N, Campbell J, Haraoui B, et al. Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage. 2002;10(11):863-869. doi: 10.1053/joca.2002.0838Bellamy N, Campbell J, Haraoui B, et al. Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage. 2002;10(11):863-869. doi: 10.1053/joca.2002.0838Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049. doi: 10.1002/art.1780290816Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049. doi: 10.1002/art.1780290816Kropf LL, Madeira M, Vieira NL, et al. Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol. 2013;32(7):991-998. doi: 10.1007/s10067-013-2219-1Kropf LL, Madeira M, Vieira NL, et al. Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol. 2013;32(7):991-998. doi: 10.1007/s10067-013-2219-1Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf). 1988;28(5):515-524. doi: 10.1111/j.1365-2265.1988.tb03686.xDons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf). 1988;28(5):515-524. doi: 10.1111/j.1365-2265.1988.tb03686.xBiermasz NR, Wassenaar MJ, van der Klaauw AA, et al. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab. 2009;94(7):2374-2379. doi: 10.1210/jc.2008-2393Biermasz NR, Wassenaar MJ, van der Klaauw AA, et al. Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. J Clin Endocrinol Metab. 2009;94(7):2374-2379. doi: 10.1210/jc.2008-2393Wassenaar MJ, Biermasz NR, Pereira AM, et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab. 2009;94(12):4671-4678. doi: 10.1210/jc.2009-1172Wassenaar MJ, Biermasz NR, Pereira AM, et al. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. J Clin Endocrinol Metab. 2009;94(12):4671-4678. doi: 10.1210/jc.2009-1172Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89(6):2789-2796. doi: 10.1210/jc.2003-032041Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89(6):2789-2796. doi: 10.1210/jc.2003-032041Scarpa R, De Brasi D, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab. 2004;89(2):598-603. doi: 10.1210/jc.2003-031283Scarpa R, De Brasi D, Pivonello R, et al. Acromegalic axial arthropathy: a clinical case-control study. J Clin Endocrinol Metab. 2004;89(2):598-603. doi: 10.1210/jc.2003-031283Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235-244. doi: 10.1530/EJE-12-0147Claessen KM, Ramautar SR, Pereira AM, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235-244. doi: 10.1530/EJE-12-0147van Thiel SW, Bax JJ, Biermasz NR, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol. 2005;153(2):231-238. doi: 10.1530/eje.1.01955van Thiel SW, Bax JJ, Biermasz NR, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol. 2005;153(2):231-238. doi: 10.1530/eje.1.01955Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853-3859. doi: 10.1210/jc.2008-0669Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853-3859. doi: 10.1210/jc.2008-0669Örük G, Tarhan F, Argın M, et al. Is every joint symptom related to acromegaly? Endocrine. 2013;43(2):404-411. doi: 10.1007/s12020-012-9770-4Örük G, Tarhan F, Argın M, et al. Is every joint symptom related to acromegaly? Endocrine. 2013;43(2):404-411. doi: 10.1007/s12020-012-9770-4

The authors declare that there are no conflicts of interest present.